title: ESR1 promoter hypermethylation does not predict atypia in RPFNA nor persistent atypia after 12 months tamoxifen chemoprevention.
abstract: OBJECTIVE
  Currently, we lack biomarkers to predict whether high-risk women with mammary atypia will respond to tamoxifen chemoprevention.
  
  
  METHODS
  Thirty-four women with cytologic mammary atypia from the Duke University High-Risk clinic were offered tamoxifen chemoprevention. We tested whether ESR1 promoter hypermethylation and/or estrogen receptor (ER) protein expression by immunohistochemistry predicted persistent atypia in 18 women who were treated with tamoxifen for 12 months and in 16 untreated controls.
  
  
  RESULTS
  We observed a statistically significant decrease in the Masood score of women on tamoxifen chemoprevention for 12 months compared with control women. This was a significant interaction effect of time (0, 6, and 12 months) and treatment group (tamoxifen versus control) P = 0.0007. However, neither ESR1 promoter hypermethylation nor low ER expression predicted persistent atypia in Random Periareolar Fine Needle Aspiration after 12 months tamoxifen prevention.
  
  
  CONCLUSIONS
  Results from this single institution pilot study provide evidence that, unlike for invasive breast cancer, ESR1 promoter hypermethylation and/or low ER expression is not a reliable marker of tamoxifen-resistant atypia.
authors: Duke University Medical Center, Durham, NC 27710, USA.
authors: Joseph C
authors: JC
authors: Baker
authors: Julie H
authors: JH
authors: Ostrander
authors: Siya
authors: S
authors: Lem
authors: Gloria
authors: G
authors: Broadwater
authors: Gregory R
authors: GR
authors: Bean
authors: Nicholas C
authors: NC
authors: D'Amato
authors: Vanessa K
authors: VK
authors: Goldenberg
authors: Craig
authors: C
authors: Rowell
authors: Catherine
authors: C
authors: Ibarra-Drendall
authors: Tracey
authors: T
authors: Grant
authors: Patrick G
authors: PG
authors: Pilie
authors: Shauna N
authors: SN
authors: Vasilatos
authors: Michelle M
authors: MM
authors: Troch
authors: Victoria
authors: V
authors: Scott
authors: Lee G
authors: LG
authors: Wilke
authors: Carolyn
authors: C
authors: Paisie
authors: Sarah M
authors: SM
authors: Rabiner
authors: Alejandro
authors: A
authors: Torres-Hernandez
authors: Carola M
authors: CM
authors: Zalles
authors: Victoria L
authors: VL
authors: Seewaldt
mesh_terms: D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000494:pharmacology*; D044963:Biopsy, Fine-Needle / Q000379:methods*; D001943:Breast Neoplasms / Q000235:genetics* / Q000473:pathology / Q000517:prevention & control*; D018890:Chemoprevention; D019175:DNA Methylation; D047628:Estrogen Receptor alpha / Q000235:genetics*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D010865:Pilot Projects; D016133:Polymerase Chain Reaction; D011237:Predictive Value of Tests; D011401:Promoter Regions, Genetic; D013629:Tamoxifen / Q000008:administration & dosage / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018931:Antineoplastic Agents, Hormonal; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D013629:Tamoxifen